Tracking Liver Scarring in Fatty Liver Disease Patients Over Time
Builds a patient group with fatty liver disease to find markers of worsening liver scarring.
Plain-language title generated from the registry record
Registry title: Establishment of NAFLD Cohort and Development of Fibrosis Markers
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Seoul Metropolitan Government Seoul National UniversitySeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Boramae Hospital
- Trial code
- NCT02206841
- Record updated
- 15 May 2025
- Original description
This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.Read full original descriptionShow less
Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis
This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.
Inclusion: Patients with histologically confirmed fatty liver disease; Patients with radiologically confirmed fatty liver disease.
Exclusion: Hepatotoxic medication (e.g. amiodarone); History of significant alcohol consumption; Viral hepatitis; Autoimmune hepatitis; Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency).